MiMedx Group, Inc. (NASDAQ:MDXG) Insider Kimberly Maersk-Moller Sells 2,111 Shares

MiMedx Group, Inc. (NASDAQ:MDXG) insider Kimberly Maersk-Moller sold 2,111 shares of the stock in a transaction on Friday, February 28th. The stock was sold at an average price of $8.40, for a total transaction of $17,732.40. Following the sale, the insider now directly owns 265,271 shares in the company, valued at $2,228,276.40. This trade represents a 0.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

MiMedx Group Trading Down 0.1 %

Shares of MiMedx Group stock opened at $8.09 on Thursday. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14. The firm has a market capitalization of $1.19 billion, a PE ratio of 14.71 and a beta of 1.97. The firm’s 50-day moving average price is $8.66 and its 200 day moving average price is $7.75.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, hitting the consensus estimate of $0.07. The firm had revenue of $92.91 million during the quarter, compared to analysts’ expectations of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. On average, sell-side analysts predict that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on MDXG shares. StockNews.com lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.00.

Institutional Trading of MiMedx Group

Several large investors have recently bought and sold shares of the business. IMG Wealth Management Inc. acquired a new position in shares of MiMedx Group during the 4th quarter worth approximately $28,000. Virtus Fund Advisers LLC purchased a new stake in MiMedx Group in the 4th quarter valued at $35,000. Van ECK Associates Corp acquired a new stake in shares of MiMedx Group in the 4th quarter worth $40,000. Tower Research Capital LLC TRC raised its holdings in shares of MiMedx Group by 77.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock worth $63,000 after acquiring an additional 2,837 shares during the period. Finally, Point72 DIFC Ltd boosted its position in shares of MiMedx Group by 127.6% during the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after acquiring an additional 4,275 shares during the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.